All CAD patients were taking at least one antiplatelet drug and lipid-lowering therapy (a statin or ezetimibe), 36 (72%) were taking either an angiotensin-converting enzyme inhibitor or an angiotensin-2 receptor blocker, 34 (68%) were on a beta-blocker, 16 (32%) on a calcium antagonist, 3 (6%) on a mineralocorticoid antagonist, and 11 (22%) were taking a diuretic. The gene discussed is AGTR2; the disease is coronary artery disorder.